Effect of local anesthesia with lidocaine on perioperative proinflammatory cytokine levels in plasma and cerebrospinal fluid in cerebral aneurysm patients by Matas, Marijana et al.
Study Protocol Clinical Trial Medicine®
OPENEffect of local anesthesia with lidocaine on
perioperative proinﬂammatory cytokine levels
in plasma and cerebrospinal ﬂuid in cerebral
aneurysm patients
Study protocol for a randomized clinical trial
Marijana Matas, MDa,
∗
, Vlatka Sotosek, MD, PhDb,c, Ana Kozmar, PhDd, Robert Likic´, MD, PhDe,f,

















Background: Cerebral aneurysm surgery has signiﬁcant mortality and morbidity rate. Inﬂammation plays a key role in the
pathogenesis of intracranial aneurysms, their rupture, subarachnoid hemorrhage and neurologic complications. Proinﬂammatory
cytokine level in blood and cerebrospinal ﬂuid (CSF) is an indicator of inﬂammatory response. Cytokines contribute to secondary brain
injury and can worsen the outcome of the treatment. Lidocaine is local anesthetic that can be applied in neurosurgery as regional
anesthesia of the scalp and as topical anesthesia of the throat before direct laryngoscopy and endotracheal intubation. Besides
analgesic, lidocaine has systemic anti-inﬂammatory and neuroprotective effect.
Primary aim of this trial is to determine the inﬂuence of local anesthesia with lidocaine on the perioperative levels of pro-inﬂammatory
cytokines interleukin-1b, interleukin-6, and tumor necrosis factor-a in plasma and CSF in cerebral aneurysm patients.
Methods: We will conduct prospective randomized clinical trial among patients undergoing craniotomy and cerebral aneurysm
clipping surgery in general anesthesia. Patients included in the trial will be randomly assigned to the lidocaine group (Group L) or to the
control group (Group C). Patients in Group L, following general anesthesia induction, will receive topical anesthesia of the throat
before endotracheal intubation and also regional anesthesia of the scalp before Mayﬁeld frame placement, both done with lidocaine.
Patients in Group C will have general anesthesia only without any lidocaine administration. The primary outcomes are concentrations
of cytokines interleukin-1b, interleukin-6 and tumor necrosis factor-a in plasma and CSF, measured at speciﬁc timepoints
perioperatively. Secondary outcome is incidence of major neurological and infectious complications, as well as treatment outcome in
both groups.
Discussion: Results of the trial could provide insight into inﬂuence of lidocaine on local and systemic inﬂammatory response in
cerebrovascular surgery, and might improve future anesthesia practice and treatment outcome.
Trial is registered at ClinicalTrials.gov: NCT03823482.
Abbreviations: ASA = American Society of Anesthesiologists, ATP= adenosine triphosphate, BBB= blood-brain barrier, CNS =
central nervous system, CSF = cerebrospinal ﬂuid, CT = computerized tomography, ECG = electrocardiography, ELISA = enzyme-
linked immunosorbent assay, ETCO2 = end-tidal carbon dioxide, GCS=Glasgow coma score, IFN = interferon, IL= interleukin, IQR
= interquartile range, ROC = receiver operator characteristics, SAH = subarachnoid hemorrhage, SpO2 = pulse oximetry, TNF =
tumor necrosis factor.
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Cerebral aneurysms are relatively common in a general
population with a prevalence of 3%. Existing treatment options
include surgical and endovascular treatment, both accompanied
by a signiﬁcant disability and mortality rate.[1] Pathophysiologi-
cal mechanisms of aneurysm etiology, their growth and factors
contributing to rupture with consequent bleeding are not fully
known yet. Recent studies emphasize the key role of inﬂamma-
tion in pathogenesis of aneurysms, their rupture, subarachnoid
hemorrhage (SAH) and early brain injury, spasm of cerebral
vessels and delayed neurological deﬁcit.[2]
The inﬂammatory response, measured by the increased levels
of pro-inﬂammatory cytokines in plasma and cerebrospinal ﬂuid
(CSF), is present during and immediately after elective neurosur-
gical procedures, as well as in patients following cerebral
aneurysm rupture.[3–5] Activation of inﬂammatory response and
cytokine release contributes to secondary brain damage and
death of neurons, leading to poorer outcome. Cytokines are
released from central nervous system (CNS) cells, such as
microglia, astrocytes, endothelial cells of the brain and neurons,
but also from activated leukocytes and lymphocytes that passed
from systemic circulation through blood-brain barrier (BBB).[6]
Speciﬁcally, the extracellular adenosine triphosphate (ATP)
released from injured brain tissue, as well as the presence of
subarachnoid blood, causes proliferation, migration, and
activation of the microglia. Activated microglia release various
cytotoxic substances that can damage brain cells, including pro-
inﬂammatory cytokines, interleukin (IL) 1b, tumor necrosis
factor alpha (TNF-a), and interferon gamma (IFNg). Released
cytokines may pass through the damaged BBB and subsequently
be detected in the blood. In addition, a systemic inﬂammatory
response may be caused by brain injury, bleeding or ischemia.
Research show that inﬂammatory cytokine levels, such as IL-6
and TNF-a, in plasma and CSF of patients with aneurysmatic
SAH correlate with the occurrence of neurological and infectious
complications as well as with the treatment outcome.[7,8]
Lidocaine is local anesthetic and antiarrhythmic drug with
other signiﬁcant systemic effects, such as anti-inﬂammatory,
neuroprotective and antimetastatic effects.[9] In neurosurgical
patient local anesthetics can be used for regional anesthesia of the
scalp and before direct laryngoscopy and endotracheal intuba-
tion with the aim of maintaining hemodynamic stability and
avoiding intracranial pressure increase. For this purpose, regional
and intravenous administration of lidocaine are both already
described.[10]
Lidocaine exerts signiﬁcant anti-inﬂammatory effect. In animal
research model, both inhaled and intravenous lidocaine,
attenuated levels of TNF-a, IL-1b, and IL-6 in lungs.[11] Another
study showed that intravenous lidocaine increase the concentra-
tion of anti-inﬂammatory cytokine IL-10 in mechanically
ventilated animal lungs.[12] Clinical studies conﬁrm that lido-
caine, whether administered locally or intravenously, reduces
levels of pro-inﬂammatory cytokines, although contradictory
data exist.[13,14]
Recent research found signiﬁcant effect of lidocaine on
microglia. Lidocaine reduces the release of IL-1b and thus
reduces the activation of the microglia as a key step of
inﬂammatory response in CNS.[15]
The pharmacological modulation of the inﬂammatory process,
which might be crucial in the pathology of cerebral aneurysms
and treatment outcome, is still the subject of scientiﬁc research.2The inﬂuence of local anesthesia with lidocaine during cerebral
aneurysm surgery on inﬂammatory response as well as on the
immediate postoperative period has so far not been systemati-
cally investigated.
We hypothesized that regional anesthesia of the scalp and
topical anesthesia of the throat, both done with lidocaine, would
signiﬁcantly decrease the levels of pro-inﬂammatory cytokines in
CSF and plasma of patients undergoing craniotomy and cerebral
aneurysm surgery. Lower concentrations of pro-inﬂammatory
cytokines might contribute to better outcome and might decrease
the incidence of systemic and CNS related postoperative
complications. Aim of this study is to determine the inﬂuence
of lidocaine administration on perioperative inﬂammatory
cytokine levels in plasma and CSF of patients undergoing
craniotomy and cerebral aneurysm surgery.2. Methods
2.1. Study design
This is an ongoing single center, prospective, randomized clinical
trial at the University Hospital Center Zagreb, which is a referral
hospital for cerebral aneurysm surgery and has case volume
necessary for the study. Trial is registered at ClinicalTrials.gov
(NCT03823482).2.2. Inclusion criteria
Patient scheduled to undergo craniotomy for cerebral aneurysm
surgery under general anesthesia will be recruited for the trial.
Inclusion criteria include age between 18 and 70 years, American
Society of Anesthesiologists (ASA) physical status I-II and written
informed consent.2.3. Exclusion criteria
Patients with severe cardiovascular (New York Heart Associa-
tion class 3 and 4) or pulmonary condition (Global Initiative for
Chronic Obstructive Lung Disease class 3 and 4) will be excluded
from the trial, as well as patients with ongoing acute infection or
immunological disease. Patients on steroid treatment due to any
reason will also be excluded. Patients with preoperative Glasgow
coma score (GCS) lower than 15 or with signiﬁcant motor deﬁcit
will also be excluded. Pregnancy and allergy to any of the
medication used in study protocol are also considered to be
exclusion criteria. Patients with signiﬁcant intraoperative blood
loss (more than 500 ml) or with prolonged surgery time (more
than 6hours) will be excluded from data analysis.2.4. Randomization
Patients who meet the criteria will be randomly allocated to the
lidocaine group or to the control group. Randomization will be
computer generated with allocation ratio 1:1. Randomization
and enrollment will be done by an independent physician who is
not directly involved in the care of the patients. Anesthesiologist
will not be blinded to the grouping, but the participants.
Unblinding could be done in case of any medical emergency. In
case of unblinding, the patient will be excluded from the trial.
Allocation concealment will be ensured with closed envelop
method, which cannot be opened until induction of the anesthesia
have been completed
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Patients included in the trial will be randomly assigned to the
lidocaine group (Group L) or to the control group (Group C).
Patients in Group L, following general anesthesia induction, will
receive topical anesthesia of the throat before endotracheal
intubation with 40mg of lidocaine and also regional anesthesia of
the scalp with 2% lidocaine in maximum dosage 4mg/kg before
Mayﬁeld frame placement. Total dosage of lidocaine will be up to
400mg. Regional anesthesia of the scalp will be performed using
technique described in relevant literature.[16] Patients in Group C
will have general anesthesia only without any lidocaine
administration. All patients will undergo craniotomy and
cerebral aneurysm clipping surgery with preoperative placement
of lumbar CSF drainage, when it is otherwise indicated
neurosurgically.
Blood samples will be taken from every patient included in the
study at four timepoints: before induction of the anesthesia
(baseline), at the time of incision, at the end of surgery and 24
hours from start of anesthesia. CSF samples will be taken from
lumbar CSF drainage system at 2 timepoints: at the time of
incision and at the end of surgery. Concentrations of IL-1b, IL-6,
and TNF-a in plasma and CSF will be measured using enzyme-
linked immunosorbent assay (ELISA) speciﬁc for each cytokine,
according to manufacturer instructions.2.6. Anesthesia management
During the surgical procedure, the following standard monitor-
ing will be used: electrocardiography (ECG), pulse oximetry
(SpO2), invasive and noninvasive blood pressure measurements,
end-tidal carbon dioxide (ETCO2), entropy, body temperature,
and urine output. Induction of general anesthesia will be
performed with fentanyl, propofol and rocuronium. After
tracheal intubation, mechanical ventilation will be commenced
tomaintain normoxia and normocapnia with tidal volume of 8 to
10ml/kg, respiratory rate of 10 to 14 per minute, fraction of
inspired oxygen of 50% and fresh gas ﬂow rate of 3 liter per
minute. Anesthesia will be induced and maintained with
continuous intravenous infusions of propofol 100 to 200mcg/
kg/minute and fentanyl 1 to 2mcg/kg/hour, adjusted to entropy
monitoring. No inhalation anesthetic agent will be used. Fluid
balance will be closely monitored and crystalloid infusions will be
used for ﬂuid therapy. Arterial blood pressure will be continu-
ously monitored and recorded. Vasoactive agents will be used to
maintain target values of mean arterial pressure (±30% of
baseline values), depending on clinical scenario, with phenyleph-
rine 0,5mcg/kg/minute or noradrenaline 0,01mcg/kg/minute.
Dosages of anesthetic drugs usedwill be recorded as well as all the
monitored clinical parameters. At the end of the surgery, patient
will be transferred to the intensive care unit where the patient will
be safely extubated. Time of extubation will also be recorded.
Monitoring of ECG, SpO2, ETCO2, and arterial blood pressure
will be continued in intensive care unit. After extubation, GCSwill
be recorded at every hour for the ﬁrst 48hours after surgery.
Patients will be monitored for neurological and infectious
complications during hospital stay and their incidence will be
recorded. Any new focalmotor deﬁcit or fall in GCS by 2 points or
more will be considered signiﬁcant, as well as any seizure
occurrence. Development of signiﬁcant vasospasm will be
diagnosed by clinical signs and conﬁrmed by transcranial Doppler
ultrasound (blood ﬂow velocity more than 180cm/seconds over3middle cerebral artery). Any major pathology found on postoper-
ative brain computerized tomography (CT) will also be recorded
(bleeding, ischemia, edema, or hydrocephalus). The study will
monitor for any potential intervention-related adverse events daily
through patient examination and chart review. All data will be
entered electronically and coded to maintain participant conﬁ-
dentiality. This will be done at the Center where the data
originated. Original forms will be stored securely for a period of 3
years after completion of the study. All investigators will be given
access to the ﬁnal data sets and we will deliver a completely
deidentiﬁed data set to an appropriate data archive for sharing
purposes.2.7. Primary outcome
The primary outcome are concentrations of IL-1b, IL-6, and
TNF-a in plasma and CSF of patients undergoing craniotomy for
cerebral aneurysm surgery under general anesthesia. These
cytokines will be measured at speciﬁc timepoints, as described.2.8. Secondary outcomes1. Incidence of neurological complications within the ﬁrst 7
postoperative days: new focal motor deﬁcit, decrease of GCS
by 2 points or more, seizure, signs of vasospasm, pathological
ﬁnding in brain CT scan.2. Incidence of infectious complications within the ﬁrst 7
postoperative days: meningitis, pneumonia, or sepsis.3. Outcome assessment will be done by using Glasgow outcome
scale at the end of hospital treatment.
2.9. Sample size calculation
Based on previous studies, we performed a sample size estimation
before recruitment with the power analysis module of STATIS-
TICA software version 10.0 (StatSoft Inc., San Diego, CA), using
a=0.05 and b=0.1.[17,18] We determined that a minimum of 20
participants was required per group for pair-wise comparisons of
our samples.2.10. Timeline
This is an 18-month study, which started inMarch 2019 and will
be ended in September 2020.2.11. Safety
The incidence of side effects during entire postoperative period
will be closely monitored and recorded, as well as adverse events
and complications. In case of any adverse events or complica-
tions, the administration of lidocaine will be immediately stopped
in Group L and patient will be excluded from further
interventions of this study.2.12. Ethics and dissemination
Before this study, permission was ﬁrst obtained from Ethics
Board of University Hospital Center Zagreb, Zagreb, Croatia
(Number 02/21 AG), and Ethics Committee of Faculty of
Medicine, University of Rijeka, Rijeka, Croatia (Number 217 0-
24-04-3-19-3). Written informed consent will be obtained from
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modiﬁcations to the protocol which may impact on the conduct
of the study, potential beneﬁt of the patient or may affect patient
safety, including changes of study objectives, study design,
patient population, sample sizes, study procedures, or signiﬁcant
administrative aspects will require a formal amendment to the
protocol. Such amendment will be approved by the aforemen-
tioned Ethics Committees and communicated through clinical-
trial.gov before implementation. Results of this trial will be
submitted for publication in peer-reviewed journal and for
presentation at scientiﬁc conference.3. Statistical analysis plan
The analysis will be conducted by Statistical Package for the
Social Sciences (SPSS) Statistics software, version 25.0 (IBM
Corporation, Armonk, NY). Continuous and ordinal data will be
presented as the median and interquartile range (IQR), while
categorical data will be presented as raw numbers and as
frequencies. Distribution of data will be tested by the
Kolmogorov-Smirnov and Shapiro-Wilk tests. Non-parametric
tests like Friedman’s 2-way ANOVAwith post-hoc Dunn test and
Mann–WhitneyU test will be used to assess pair-wise differences
between related and independent variables with non-normal
distribution. Data with normal distribution will be analyzed by
Student t test. Correlations will be analyzed with Spearman test.
For sensitivity-speciﬁcity measurements, the receiver operator
characteristics (ROC) curve estimation will be used. Values of
P< .05 is considered signiﬁcant. An interim-analysis is performed
on the primary endpoint when 50% of patients have been
randomized. The interim-analysis is performed by an indepen-
dent statistician, blinded for the treatment allocation.4. Discussion
Increasing data conﬁrm beneﬁt of local anesthetics in patients
undergoing craniotomy. Lidocaine can diminish autonomic
response to the placing of Mayﬁeld’s frame when administered
as scalp block or local inﬁltration. Regional and intravenous
administration of lidocaine can reduce postoperative pain.
Another indication of local anesthetic use is to reduce autonomic
nervous system response to direct laryngoscopy and endotracheal
intubation.[10]
Recent studies suggest systemic anti-inﬂammatory effect of
local anesthetics in craniotomy patients, but also acknowledge
the need for further investigation.[19,20] Lidocaine has proven
anti-inﬂammatory local and systemic effect, even at low plasma
concentrations.
Therefore, we propose a clinical trial to investigate effect of
lidocaine administration on perioperative levels of pro-inﬂam-
matory cytokines, whichmight be crucial in pathology of cerebral
aneurysms. Measuring concentrations of IL-1b, IL-6, and TNF-a
in plasma and CSF might provide insight regarding the effect of
lidocaine on local and systemic inﬂammatory response.
Furthermore, this trial will investigate potential impact of
decreased inﬂammatory response on major neurological and
infectious complications in early postoperative period, as well as
on outcome of the treatment.
Trial will test the hypothesis that lidocaine administration
decreases concentrations of IL-1b, IL-6, and TNF-a in plasma
and CSF in patients undergoing cerebral aneurysm surgery.
Results of the trial could provide insight into inﬂuence of4lidocaine on local and systemic inﬂammatory response in
cerebrovascular surgery, and might improve future anesthesia
practice and treatment outcome.Acknowledgments
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